BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15194050)

  • 21. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
    Tanji S
    Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer.
    Fewell JG; Matar M; Slobodkin G; Han SO; Rice J; Hovanes B; Lewis DH; Anwer K
    J Control Release; 2005 Dec; 109(1-3):288-98. PubMed ID: 16269201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
    Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
    Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model.
    Tan J; Newton CA; Djeu JY; Gutsch DE; Chang AE; Yang NS; Klein TW; Hua Y
    Cancer Res; 1996 Aug; 56(15):3399-403. PubMed ID: 8758901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation.
    Maurer-Gebhard M; Schmidt M; Azemar M; Stöcklin E; Wels W; Groner B
    Hybridoma; 1999 Feb; 18(1):69-75. PubMed ID: 10211791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
    Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
    Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effect of low cytotoxic linear polyethylenimine and multiarm polyethylene glycol: study of physicochemical properties and in vitro gene transfection.
    Namgung R; Kim J; Singha K; Kim CH; Kim WJ
    Mol Pharm; 2009; 6(6):1826-35. PubMed ID: 19791796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenoviral vectors modified by heparin-polyethyleneimine nanogels enhance targeting to the lung and show therapeutic potential for pulmonary metastasis in vivo.
    Wei W; Mu Y; Li X; Gou M; Zhang H; Luo S; Men K; Mao Y; Qian Z; Yang L
    J Biomed Nanotechnol; 2011 Dec; 7(6):768-75. PubMed ID: 22416575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
    Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
    Yockman JW; Kim WJ; Chang CW; Kim SW
    Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers.
    Mahato RI; Lee M; Han S; Maheshwari A; Kim SW
    Mol Ther; 2001 Aug; 4(2):130-8. PubMed ID: 11482984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
    Seki N; Hayakawa Y; Brooks AD; Wine J; Wiltrout RH; Yagita H; Tanner JE; Smyth MJ; Sayers TJ
    Cancer Res; 2003 Jan; 63(1):207-13. PubMed ID: 12517799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.